NeuMoDx Molecular Systems


Our patented, “sample to result” platform offers market-leading ease of use, true continuous random-access and rapid turnaround time while achieving optimal operational and clinical performance for our customers and their patients.


The NeuMoDx™ Molecular, a QIAGEN company are a family of scalable platforms that fully integrate the entire molecular diagnostic process from “sample to result”. The NeuMoDx™ 288 and the NeuMoDx™ 96 Molecular Systems are fully automated, continuous random-access analyzers utilizing our proprietary NeuDry™ reagent technology, which integrates magnetic particle affinity capture and real time Polymerase Chain Reaction (PCR) chemistry in a multi-sample microfluidic cartridge. This technology, combined with a platform, uniquely incorporates robotics and microfluidics resulting in higher throughput, improved performance and increased efficiency by eliminating the waste associated with technologies that require reconstitution of lyophilized reagents.

NeuMoDx has a strong IP portfolio that includes greater than 20 US patents along with corresponding foreign patents and applications.


Create a scalable family of molecular testing platforms easily integrated into the molecular diagnostic process. Enable laboratory professionals to operate more efficiently and cost-effectively, thereby increasing the use of molecular diagnostic testing by medical providers to better identify and treat disease early.

Our Solutions



Our Leadership

  • Sundu Brahmasandra
    President and COO, NeuMoDx™ Molecular Sundu Brahmasandra

    Sundu serves as the President of NeuMoDx™ Molecular. Most recently, he served as the President of Life Magnetics, Inc. a spin-out from the University of Michigan developing a novel, non-microscope based platform for real-time monitoring of cell growth, death, and other binding events. Prior to Life Magnetics, Sundu served as a VP of R&D/Assay Development in the Infectious Disease division at BD Diagnostics. Prior to BD, Sundu was Co-Founder and V.P. Product Development of HandyLab, Inc., where he led the development & validation of the Jaguar molecular diagnostic platform as well as proprietary nucleic acid preparation technologies and a multitude of real-time PCR assays spanning molecular diagnostics, food-borne pathogen detection, GMO testing, and other applications. HandyLab was acquired by BD in Nov 2009 for more than $275 million.

    Sundu received his BS from the Indian Institute of Technology, Chennai and a Ph.D. in Chemical Engineering from the University of Michigan in 2001.

  • Daniel Harma
    Chief Commercial Officer, NeuMoDx™ Molecular Daniel Harma

    Dan serves as the Chief Commercial Officer at NeuMoDx™ Molecular where he is responsible for building and leading the infrastructure to market and support the NeuMoDx™ Molecular solutions. Previously, Dan was with Abbott Diagnostics for over 25 years serving in various commercial leadership roles including Sales, Marketing, Enterprise Account Management and International General Management. He has a proven track record of hiring, developing and leading top performing commercial organizations. Dan received his Bachelors of Business Degree from the University of Wisconsin – Whitewater and MBA from Loyola University-Chicago.

  • Nahed Mohsen
    VP of Regulatory and Clinical Affairs, NeuMoDx™ Molecular Nahed Mohsen

    Dr. Mohsen serves as the VP of Regulatory Clinical Affairs at NeuMoDx Molecular. Most recently,
    Dr. Mohsen served as the VP of Regulatory Affairs and Quality Assurance at ISS. Earlier in her career Dr. Mohsen was the lead inventor and developer of a migraine aerosol medication at Sheffield Pharmaceuticals which later became MAP Pharmaceuticals (MAP stands for the initials of the 3-inventor team lead by Mohsen) prior to its purchase by Allergan for about $1 billion. Dr. Mohsen has extensive experience in design, development, and optimization of drug-device product combinations for liquid, propellant-based and dry powder-based delivery systems and formulations. Her main area of expertise is in physical, chemical, and biological characterizations and analysis of polymer-based biomaterials. From 2007 to 2012, Dr. Mohsen was a senior medical product regulatory and quality assurance consultant and served as an aerosol expert witness for medical devices and pharmaceutics litigation cases at Exponent, Inc. Prior to joining Exponent, Dr. Mohsen was a Manager of Scientific Communications and Medical Writing at UnitedHealth Group. From 1996 to 2003, Dr. Mohsen held a series of scientific and product development positions including Chief Scientist at Sheffield Pharmaceutical and Aeroquip Corporations. Dr. Mohsen received a Ph.D. in Bioengineering, a M.S. in Bioengineering, a M.S. in Industrial and Systems Engineering, a B.A. in Psychology and a B.S. Biochemistry all from the University of Michigan. Dr. Mohsen holds 11 issued patents and has over 40 journal publications and international conference presentations.

Join Us

At NeuMoDx™, we work together with the common goal of designing and developing revolutionary molecular diagnostic solutions for hospital and clinical reference laboratories. We are always looking for caring, energetic individuals to join our team.



We are excited to announce that QIAGEN has acquired all shares of NeuMoDx Molecular, Inc. The addition of NeuMoDx’s medium- and high-throughput molecular systems further expands QIAGEN’s portfolio of molecular diagnostics instruments, bolstering our leadership in automated molecular testing. We are proud to welcome NeuMoDx to our family of PCR solutions that make improvements in life possible.

To learn more, click here.